[Skip to Content]
[Skip to Content Landing]

An Atypical Rash on the Chest

Educational Objective
Based on this clinical scenario and the accompanying image, understand how to arrive at a correct diagnosis.
1 Credit CME

A 71-year-old man presented to the dermatologist with a 6-week history of a rapidly progressing rash and swelling of the left side of the chest wall. He had noticed the rash a few days after receiving the second dose of an mRNA COVID-19 vaccine (Moderna). He denied itching, weeping, bleeding, or discharge from the rash or the nipple. He had a history of metabolic syndrome treated with antihypertensives and oral hypoglycemics. The physical examination showed a morbidly obese White man.

Please finish quiz first before checking answer.

You answered correctly!

Read the answer below and download your certificate.

You answered incorrectly.

Read the discussion below and retake the quiz.

C. Inflammatory breast cancer

The histopathological findings of the lymph node biopsy showed invasive ductal carcinoma with micropapillary features. The immunohistochemical staining was positive for GATA-3 and CK-7, along with 40% ER expression. Next-generation sequencing showed a microsatellite stable status and variations in the CDKN2, ERBB2, and PIK3CA genes. Based on these findings, the patient was diagnosed with inflammatory breast cancer (IBC) with invasive ductal carcinoma and treated with systemic chemotherapy. It is important to note that the history of receiving the COVID-19 mRNA vaccine is a red herring in this case.

It is challenging to differentiate between adnexal tumors and breast cancer when the patient presents with a cutaneous lesion of the breast. The current patient presented with a widespread rash, retracted nipple, and a peau d’orange appearance of the skin commonly seen in patients with IBC.1 However, peau d’orange skin can also be seen in patients with cellulitis and radiation-induced lymphatic blockage.2 The atypical cells obtained from a skin punch biopsy stained positive for GATA-3 and CK-7. GATA-3 belongs to the GATA family of zinc-finger transcription and is involved in the development and morphogenesis of breast tissue.3 It is commonly expressed in ER-positive breast cancers. However, the expression of GATA-3 is not exclusive to breast cancer and has been reported in tumors of the salivary gland, urothelial system, skin and adnexa, mesothelioma, and pancreas.4 Breast glands are considered to be modified and highly specialized apocrine glands. Hence, they share structural and functional homology with sweat glands.5

Survey Complete!

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Ankit Mangla, MD, University Hospitals Seidman Cancer Center, 11100 Euclid Ave, Cleveland, OH 44106 (ankit.mangla@uhhospitals.org).

Published Online: December 29, 2022. doi:10.1001/jamaoncol.2022.6126

Conflict of Interest Disclosures: None reported.

Additional Contributions: We thank the patient for granting permission to publish this information.

References
1.
Giordano  SH , Hortobagyi  GN .  Inflammatory breast cancer: clinical progress and the main problems that must be addressed.   Breast Cancer Res. 2003;5(6):284-288. doi:10.1186/bcr608PubMedGoogle ScholarCrossref
2.
DeKraker  C , Gomez  JA , Arifin  A , Perera  FE .  Postradiation breast erythema, skin thickening, and peau d’orange.   JAAD Case Rep. 2022;23:96-98. doi:10.1016/j.jdcr.2022.02.038PubMedGoogle ScholarCrossref
3.
Kouros-Mehr  H , Slorach  EM , Sternlicht  MD , Werb  Z .  GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland.   Cell. 2006;127(5):1041-1055. doi:10.1016/j.cell.2006.09.048PubMedGoogle ScholarCrossref
4.
Voduc  D , Cheang  M , Nielsen  T .  GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.   Cancer Epidemiol Biomarkers Prev. 2008;17(2):365-373. doi:10.1158/1055-9965.EPI-06-1090PubMedGoogle ScholarCrossref
5.
Mentrikoski  MJ , Wick  MR .  Immunohistochemical distinction of primary sweat gland carcinoma and metastatic breast carcinoma: can it always be accomplished reliably?   Am J Clin Pathol. 2015;143(3):430-436. doi:10.1309/AJCP2N1AFXEFOVYEPubMedGoogle ScholarCrossref
6.
Wallace  ML , Longacre  TA , Smoller  BR .  Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms.   Mod Pathol. 1995;8(9):897-901.PubMedGoogle Scholar
7.
Fusco  N , Malapelle  U , Fassan  M ,  et al.  PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer.   Front Oncol. 2021;11:644737. doi:10.3389/fonc.2021.644737PubMedGoogle ScholarCrossref
8.
Slamon  DJ , Godolphin  W , Jones  LA ,  et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.   Science. 1989;244(4905):707-712. doi:10.1126/science.2470152PubMedGoogle ScholarCrossref
9.
Le  LP , Dias-Santagata  D , Pawlak  AC ,  et al.  Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.   PLoS One. 2012;7(10):e47290. doi:10.1371/journal.pone.0047290PubMedGoogle ScholarCrossref
10.
Spigel  JJ , Evans  WP , Grant  MD , Langer  TG , Krakos  PA , Wise  DK .  Male inflammatory breast cancer.   Clin Breast Cancer. 2001;2(2):153-155. doi:10.3816/CBC.2001.n.020PubMedGoogle ScholarCrossref
AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
  • 1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
  • 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
  • 1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
  • 1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close